Patent classifications
C07D261/06
COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE
Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.
COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE
Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.
Inhibitors of Bromodomains
The present disclosure relates to compounds capable of acting as covalent inhibitors of bromodomains and the therapeutic use of these inhibitors.
Inhibitors of Bromodomains
The present disclosure relates to compounds capable of acting as covalent inhibitors of bromodomains and the therapeutic use of these inhibitors.
ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
The present invention provides compounds of Formula I:
##STR00001##
pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
The present invention provides compounds of Formula I:
##STR00001##
pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF
Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-α inhibitors.
HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF
Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-α inhibitors.
N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT
The present invention relates to N-(5-arylamido-2-methylphenyl)-5-methylisoquoxazole-4-carboxamide derivative, or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising same. The compound according to the present invention exhibits an FMS kinase inhibitory activity and thus can be used as pharmaceutical composition for preventing and treating diseases associated therewith.
N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT
The present invention relates to N-(5-arylamido-2-methylphenyl)-5-methylisoquoxazole-4-carboxamide derivative, or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising same. The compound according to the present invention exhibits an FMS kinase inhibitory activity and thus can be used as pharmaceutical composition for preventing and treating diseases associated therewith.